Diego Adrianzen-Herrera: Our study on MDS and autoimmune disease in Blood Advances
Diego Adrianzen-Herrera, Assistant Professor of Medicine UVM Larner Med, shared a post on Twitter, saying:
“Our study on MDS and autoimmune disease (AD) in Blood Advances.
A population analysis in NCI Healthcare Delivery Research (HDRP)‘s SEER-Medicare database: 15,227 MDS patients, 16% with AD.
Preexisting AD associated with 11% decreased risk of mortality (any cause). Systemic immunosuppression preceding MDS in ~7% patients and associated with 10% increased mortality. Preexisting AD associated with higher transfusion dependence but no difference in HMA/HSCT use.
Effect of preexisting AD on the risk of AML differed depending on histology.
Preexisting AD linked to 1.9-fold higher risk of AML in RA/RARS but no significant effect in other groups.
We hope these findings inform further research on inflammation-driven clonal dynamics for a large number of MDS patients with concomitant AD.”
For the article click here.
Source: Diego Adrianzen-Herrera/Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023